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Abstract
Suboxone films are U.S. Food and Drug Administration approved to treat opioid dependence. While the
package insert states that films should not be cut, physicians often prescribe film fractions for treatment
and tapering. There is no data to support this practice, and this study was initiated to evaluate cutting
methods, content uniformity, and stability of split films. Suboxone 8-mg buprenorphine/2-mg naloxone
films were split using four methods: 1) ruler/razor cut, 2) scissor cut, 3) fold/rip, and 4) fold/scissor cut.
United States Pharmacopeia Chapter <905> was used to evaluate the weight variation and content
uniformity of split films. The stability of split films stored in polybags was evaluated over 7 days. A
stability-indicating high-performance liquid chromatography method was used for content uniformity and
stability evaluation. The weight variation results were acceptable for the half films from all four cutting
methods, but this was not true for the quarter films. The method of ruler/razor cut was determined most
favorable and used for the content uniformity test. Based on the high-performance liquid chromatography
results, the half films from the ruler/razor cut method met the passing criteria of United States
Pharmacopeia Chapter <905> with acceptance values of 9.8 to 10.4 for buprenorphine and 8.4 to 11.5 for
naloxone (≤15 is considered passing). The stability results indicated that both actives retained >97.7% of
initial strength. Four cutting methods were found to be acceptable for splitting Suboxone films into half
but not quarter fractions. The half films from the ruler/razor cut method also passed United States
Pharmacopeia Chapter <905> content uniformity test. Both actives remained stable for 7 days when the
half films were stored in polybags at room temperature.
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Introduction
In 2016, an estimated 2.1 million individ
uals were reported to have substance-use
disorder related to opioid pain medica
tions.^ Currently, there are three treatment
options for opioid use disorder: 1) metha
done, 2) buprenorphine (with or without
naloxone), and 3) naltrexone.^ Among these,
buprenorphine represents a preferred treat
ment option due to its unique mechanism of
action as a partial agonist at the mu opioid
receptor with high affinity and slow dis-

The authors are affiliated with St. John
Fisher College, Rochester, New York.

Abstmct
Suboxone films are U.S. Food and Drug Administration approved to treat
opioid dependence. White the package insert states that films should not be
cut, physicians olten prescribe film fractions for treatment and tapering. There
is no data to support this practice, and this study was initiated to evaluate
cutting methods, content uniformity, and stability of split films. Suboxone
8-mg buprenorphine/2-mg naloxone films were split using four methods: 1)
ruler/razor cut, 2) scissor cut, 3) fold/rip, and 4) fold/scissor cut. United States
^mmacopela Chapter <905> was used to evaluate the weight variation and
content uniformity of split films. The stability of split films stored in polybags
was evaluated over 7 days. A stability-indicating high-performance liquid
chromatography method was used for content uniformity and stability
evaluation. The weight variation results were acceptable for the half films from
all four cutting methods, but this was not true for the quarter films. The method
of ruler/razor cut was determined most favorable and used for the content
uniformity test. Based on the high-performance liquid chromatography results,
tbe half films from the ruler/razor cut method met the passing criteria of United
States Pharmacopeia Chapter <905> with acceptance values of 9.8 to 10.4 for
buprenorphine and 8.4 to 11.5 for naloxone (^15 Is considered passing). The
stability results indicated that both actives retained >97.7% of initial strength.
Fmir cutting methods were found to be acceptable for splitting Suboxone films
into half but not quarter fractions. The half films from the ruler/razor cut
method also passed United States Pharmacopeia Chapter <905> content
uniformity test. Both actives remained stable for 7 days when the half films
were stored in potybags at room temperature.

sociation.® This partial agonist property
increases the safety profile of buprenor
phine because the ceiling effect limits the
potential life-threatening side effects asso
ciated with overdose.
The combination of buprenorphine with
naloxone is used as an abuse deterrent
strategy.^’® Naloxone is an opioid antagonist,
and it has a relatively low bioavailability via
the oral, sublingual, or buccal routes. When
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the buprenorphine/naloxone dosage forms
are used as directed, naloxone has little to
no effect. If a patient tries to adulterate the
product for intravenous administration, the
naloxone would become bioavailable and
precipitate withdrawal. Patients initiated
on buprenorphine/naloxone therapy may
stay on therapy indefinitely; however, taper
ing a patient off therapy is common in clini
cal practice. Both American and Canadian
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guidelines state that discontinuation of buprenorphine products
may be a slow and prolonged process, possibly months to years.®'^
However, neither the guidelines nor the product labeling provide
any recommendations on the tapering dose or schedule.
Among the buprenorphine/naloxone dosage forms, the Suboxone
sublingual films are frequently prescribed for opioid dependence
treatment emd tapering. Despite clear product labeling that films
should not be cut or torn,® personal communications with commu
nity pharmacies indicate that patients are often prescribed to use
partial films such as I'/z or 114 films. Internet community discus
sion boards and pharmacy benefits management services have also
discussed cutting the films £is a means to save cost and/or allow for
dose titration.®'^® Some websites focus on cutting the films to assist
with dose tapering, with recommendations for cutting the film into
as small as 1/16 of the original size.^° A literature search did not find
any reliable published data to support such practices.
Current data does not indicate if the active ingredients in the
film are uniformly distributed across the entire film, making the
reliability of dose accuracy in split films unclear. Suboxone films
do not contain any scoring or perforation to allow for accurate split
ting, increasing the potential for dose variability among split-film
fractions. Another potential source of dose variation is the stabil
ity of the split films. Suboxone films are packaged individually in
polyester/foil laminated pouches intended for single use.® Once
opened, it is uncertain if the active ingredients remain stable over
time. As shown in FIGURE 1, the chemical structures of buprenorphine
and naloxone® contain several functional groups which are prone to
hydrolysis and oxidation.
The lack of data supporting the practice of film splitting lends
itself for study. The purpose of this study is to evaluate the accuracy
of common methods used to cut Suboxone films and to assess the
cut fractions for content uniformity as well as stability outside the
original packaging.

A total of 18 whole films (from three different lots) were used for
each splitting method. Individuals completing the film splitting
were provided with the written instructions shown in TA BIE1. All
methods were performed on a clean, glass ointment slab while
wearing gloves. Each film was cut midway of the long sides of the
film into halves or quarters.
WEIGHT VARIATION OF SPLIT FILMS
The weight variation approach from United States Pharmacopeia
(USP) Chapter <905> was used with modification to evaluate and

FIGURE 1.
CHEMICAL STRUCTURES OF (A) BUPRENORPHINE
HYDROCHLORIDE AND (B) NALOXONE HYDROCHLORIDE.®

A

TABIE1.
FILM-SPLITTING METHODS AND INSTRUCTIONS.
SPLITTING
METHOD

Ruler/F!azor Cut

Methods
MATERIALS
Multiple lots of Suboxone (8 mg buprenorphine and 2 mg naloxone)
sublingual films, manufactured by Indivior Inc. (NDC12496-1208-1;
Richmond, Virginia), were purchased between 2016 tuid 2018. For
the high-perform£uice liquid chromatography (HPLC) method, aU
solvents were purchased from Fisher Scientific (Fair Lawn, New
Jersey); polytetrafluoroethylene (PTFE) syringe filters, 0.45-|xm
pore size, and 15-mm diruneter, were purchased from Phenomenex
(Torrance, California). For the stability study of split-film fractions,
3" X 5" and 2-mil low-density polyethylene bags (polybags) were pur
chased from Total Pharmacy Supply (Arlington, Texas).
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INSTRUCTIONS

Use the ruler to measure the longer sides of the film.
Mark the halfway points by scoring the film with the
razor.
Line up the ruler across both marks scored in the film.
Use the razor to cut the film in half by connecting both
halfway points while applying pressure to the ruler to
ensure the film does not move.

Scissor Cut

1. Visually estimate the halfway points of the longer sides
of the film without using any measuring devices.
2. Use the scissors to cut the film across the estimated
halfway points.

Fold/Rip

1 Fold the film in half and apply pressure to form a crease.
2. Unfold the film.
3. Pinch both halves of the film on opposite sides of the
crease.
4. Tear the film by pulling one side towards your body and
the other side away, rather than pulling both pieces to
the side.

Fold/Scissor Cut

1 Fold the film in half and apply pressure to form a crease.
2. Unfold the film.
3. Use the scissors to cut the film along the crease.

FILM SPLITTING
Four splitting methods were evaluated in this study: 1) ruler/razor
cut, 2) scissor cut, 3) fold/rip, and 4) fold/scissor cut. The specific
details ofeach method are described in TRBIE1 and shovm in FIGURE 2.

B
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compare the accuracy and variability of
the four splitting methods.^^ Each whole
film was weighed prior to splitting, and this
value was used to calculate the expected
weight of the half and quarter films. After
splitting, the half or quarter portions were
immediately weighed. The weight of each
split film was divided by the expected value
and expressed as the percent expected
weight. The standard deviation (SD) was
calculated for each splitting method, and
an SD of <6% was considered acceptable.^^
For direct comparison across the splitting
methods, the absolute value of the weigh
difference (observed weight - expected
weight) was also calculated for each split
film and used for student t-test analysis.
Statistical significance was established if P
was <0.05. As a control for potential mois
ture uptake/loss, a set of three films were
removed from the foil packets and exposed
to the same laboratory atmosphere for the
typical duration of the experiments; no sig
nificant change in weight was observed.
DRUG CONTENT UNIFORMITY OF
SPLIT FILMS
Based on the weight variation results,
splitting the films into halves was accept
able, and ruler/razor cut was the method of
choice. The content uniformity test of USP
Chapter <905>^^ was then carried out using
an HPLC method to quantitate the amount of
the two active ingredients in the split films.
Ten whole and ten half films were evalu
ated as per USP requirement. The ten half
films were obtained by splitting five whole
films using the ruler/razor cut method. Each
whole or half film was dissolved in a suf
ficient amount of water to yield a theoretical
concentration of 80 Bg/mL buprenorphine
and 20 fig/mL naloxone. About 1-mL aliquot
from each sample was filtered through a
PTFE syringe filter and collected in a vial
for the HPLC assay. The content uniformity
test was conducted on three separate lots
of the films with each lot being evaluated
on a different day. The percent label claim
was calculated for each lot, and the mean
and standard deviation values were used
to calculate the acceptance value (AV) as

described in USP <905>.’^^ An AV of <15 was
considered passing.
STABILITY OF SPLIT FILMS
A 7-day stability study was conducted to
evaluate the physical and chemical stabil
ity of the split films outside the original
polyester/foil pouch. Films were removed
from packaging and split in half. Each half
film was placed into a polybag and stored
at room temperature. On Day 0,1,3, and
7, three replicate samples were pulled for
analysis by visual inspection and HPLC.
Each half film was dissolved in a sufficient
amount of water to yield a theoretical con
centration of 80 |lg/mL buprenorphine
and 20 Bg/mL naloxone. Standards were
included for the HPLC assay on each day for
calibration purpose. Samples were consid
ered stable if there was less than 10% loss of
each active.

VISUAL REPRESENTATION OF THE
FOUR FILM-CUTTING METHODS.
A. Ruler/Razer Cut

D. Fold/Scissor Cut

HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY ASSAY
A stability-indicating HPLC method was
developed to assay the content of buprenor
phine and naloxone in the films and to
monitor their stability when stored outside
the original packaging. The analysis was
performed using a Shimadzu LC-2010AHT
system (Shimadzu Scientific Instruments,
Marlborough, Massachusetts) with a
Phenomenex C18 column (Kinetex, 150 x
4.6 mm, 5 Bm, 100 A). The mobile phase
consisted of two channels: A = water with
0.1% v/v TFA and B = acetonitrile with
0.1% v/v TFA. Due to the vastly different
polarity of the two actives, a linear gradi
ent was used from 15% to 55% of B over 10
minutes with a 5-minute re-equilibration
period. The column oven temperature
was maintained at 40°C, and the flow rate
was 0.8 mL/min. All samples were passed
through the PTFE 45-Bm syringe filters
prior to analysis, and the injection volume
of each sample was 50 bL. The UV detection
wavelength was set at 280 nm. Under these
conditions the retention time for naloxone
was around 4.0 minutes and buprenorphine
around 9.8 minutes. A representative chro
matogram is shown in FIEIRE 3.
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Standard solutions of naloxone and
buprenorphine were prepared for calibra
tion purpose. Due to the regulatory barri
ers to obtain pure buprenorphine powder,
calibration standards were prepared using
Suboxone films (one from each correspond
ing lot) with the assumption that they
contain 100% of the label claim quantity of
each active. The concentrations of the stan
dard solutions ranged from 64/16 BS/mL
to 96/24 BS/mL buprenorphine/naloxone,
covering 80% to 120% of the theoretical
concentration of study samples. A calibra
tion curve was constructed on each analysis
day by linear regression of the peak area and
drug concentration; separate curves were
made for buprenorphine and naloxone. All
calibration curves had a value of 0.99 or
better, confirming linearity over the con
centration range of interest.
A forced degradation study was con
ducted to verify the ability of the above
gradient HPLC method to separate the
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potential degradation products from the two active ingredients. An
80/20 |tg/mL buprenorphine/naloxone solution was prepared by
dissolving a Suboxone film in water. The solution was divided into 4
different samples.
• Sample #1 was adjusted to a pH of 2 with IM hydrogen chloride and
incubated in a 60°C oven.

FIGURE 3.
A REPRESENTATIVE CHROMATOGRAM OF BUPRENORPHINE
AND NALOXONE USING THE HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY METHOD DEVELOPED FOR THE
CONTENT UNIFORMITY AND STABILITY EVALUATION.

• Sample #2 was adjusted to a pH of 12 with IM sodium hydroxide and
incubated in a 60°C oven.

Buprenorphine

• Sample #3 was spiked with 3% (final concentration) hydrogen
peroxide and incubated in a 60°C oven.
• Sample #4 was spiked with 3% (final concentration) hydrogen peroxide
and was stored at room temperature and exposed to direct sunlight.

After 48 hours, complete degradation of both actives was
observed in Sample #3 (peroxide/60°C). A significant amount of
degradation (32% to 65%) was also observed for Sample #2 (pH
12/60°C) and Sample #4 (peroxide/light). Both actives remained
stable in Sample #1 (pH 2/60°C). All the degradation products were
separated from the two active ingredients, and no interfering peaks
were observed. The gradient HPLC method was considered to be
stability indicating and suitable for the content uniformity and sta
bility evaluation.

Results and Discussion
While multiple sources suggested that patients are splitting
Suboxone sublingual films, no data are available to support this
practice. Several studies conducted on traditional tablets provided
context and discussed challenges associated with splitting dos
age forms.^^'^'* Sublingual films are a relatively new class of dosage
forms with unique properties. To the authors’ knowledge, this is the
first study to evaluate film-splitting methods and content unifor
mity of the resulting film fractions.

1 Naloxone

0.0

2.5

5.0

7.5

10.0

12.5

15.0

Minutes

IftBLE 2.
WEIGHT VARIATION RESULTS OF THE SPLIT FILMS FOR THE
FOUR SPLITTING METHODS.
% EXPECTED WEIGHT, MEAN ± SD

SPLITTING
METHOD

HALF FILMS
(«=36)

QUARTER FILMS
{»=72)

Ruler/Razor Cut

98.9 ± 3.4

99.2 + 5.2

Scissor Cut

99.1 ± 4.6

98.8 ± 6.8

Fold/Rip

98.9 + 4.5

97.2 ± 7.3

Fold/Scissor Cut

98.4 ± 4.8

97.3 ± 7.1

EVALUATION OF FILM-SPLITTING METHODS
All four splitting methods were carried out successfully without
major handling issues. However, several limitations were observed.
Due to the small size of the film, all methods required manual dex
terity and visual acuity. The films also did not tear easily along a
fold, so it was important to follow the exact directions included in
Table 1 for the fold/rip method. Cutting accurately along the fold
using scissors was also found to be more difficult than expected.
The weight variation results of the split films are summarized in
TABLE 2. For the half films, the standard deviation of the four splitting
methods ranged from 3.4% to 4.8%, which met the passing crite
ria of 6%. However, for the quarter films, the standard deviation
increased for each splitting method, and only the ruler/razor cut
method passed the test with a value of 5.2%. Similar trends were
observed from the student t-test analysis of the absolute weight dif
ferences (actual - expected) among the four splitting methods as
shown in TABLE 3. For half films, using scissors to split the films led
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to a significantly greater weight difference compared to the other
three splitting methods combined (ruler/razor, fold/rip, fold/scis
sor); 0.85 vs. 0.60, P=0.032. The quarter films indicated a similar
trend with the two scissor methods yielding greater weight differ
ences; however, only the results of the fold/scissor method were
statistically significant (0.60 vs. 0.50, P=0.013). Additionally for
the quarter films, the fold/rip method had a significantly smaller
weight difference compared to the other three methods (0.48 vs.
0.55, P=0.025); this might be due to the fact that the other three
methods included the two scissor methods.
Based on the overall weight results, splitting the Suboxone
(8 mg buprenorphine/2 mg naloxone) films into halves was
considered acceptable using all four cutting methods, with the
scissor cut method being the least consistent. However, splitting
the films into quarters or beyond was not acceptable due to sig
nificant weight variation.
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TABLE 3.
COMPARISON OF THE FOUR SPLITTING METHODS USING THE ABSOLUTE WEIGHT DIFFERENCE OF THE SPLIT FILMS.
SPLITTING
METHODS

HALF FILMS

QUARTER FILMS

MEAN (SD)

MEDIAN (IQR)

P-VALUE

MEAN (SD)

MEDIAN (IQR)

F-VALUE

Ruler/Razor Cut
Other 3 Methods

0.69 (0.49)
0.84 (0.76)

0.60 (0.35 to 0.90)
0.65 (0.35 to 1.10)

0.567

0.54 (0.40)
0.67 (0.58)

0.44 (0.23 to 0.69)
0.55 (0.25 to 0.94)

0.184

Scissor Cut
Other 3 Methods

0.93 (0.59)
076 (0.73)

0.85 (0.48 to 1.40)
0.60 (0.30 to 0.95)

0.032

0.67 (0.47)
0.63 (0.56)

0.55 (0.28 to 1.00)
0.50 (0.23 to 0.85)

0.285

Fold/Rip
Other 3 Methods

0.73 (0.82)
0.83 (0.66)

0.50 (0.25 to 0.85)
0.75 (0.40 to 1.10)

0.075

0.58 (0.65)
0.66 (0.50)

0.48 (0.16 to 0.78)
0.55 (0.28 to 0.94)

Fold/Scissor Cut
Other 3 Methods

0.86 (0.84)
0.78 (0.65)

0.68 (0.30 to 1.00)
0.65 (0.35 to 1.00)

0.837

0.77 (0.58)
0.60 (0.52)

0.60 (0.38 to 1.10)
0.50 (0.23 to 0.82)

0.025

1

0.013

Absolute weight difference (mg) = | actual weight (mg) - expected weight (mg) 1. IQR = interquartile range; SD = standard deviation.
Note: The bolded results represent a statistically significant difference for the splitting method when compared to the other methods.

CONTENT UNIFORMITY OF SPLIT FILMS
While the weight variation results provided useful informa
tion, direct measurement of the active ingredients by HPLC was
necessary to confirm the actual drug contents in the split films.
To this end, the content uniformity test procedure of USP <905>
was applied to analyze the half films prepared by the ruler/razor
cut method.^^ Three different lots were tested in case there was
any significant lot-to-lot variability. The whole films were also
analyzed for comparison purpose. The content uniformity Euialysis was performed for both buprenorphine and naloxone, and the
acceptance value (AV) was calculated using the formula in USP
<905>. As shown in TABLE 4, the AV results of buprenorphine ranged
from 7.2 to 12.1 for the whole films and 9.8 to 10.4 for the half films.
Similarly in Table 5, the AV results of naloxone ranged from 8.2 to
11.1 for the whole films and 8.4 to 11.5 for the half films. According
to USP <905>, an AV of < 15 is considered passing.^^ Based on this
criterion, the content uniformity of buprenorphine and naloxone
was considered acceptable in the half films from all three lots.
Additionally, the AV values of the half films were comparable to
those of the whole films.

TABLE A.
CONTENT UNIFORMITY RESULTS OF BUPRENORPHINE IN
WHOLE AND SPLIT FILMS.

SAMPLE

NUMBER
OF UNITS

International Journal of Pharmaceutical Compounding
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AV

7.2

Whole film, Lot 1

10

105 ± 1.43

Whole film, Lot 2

10

107 ± 2,73

12.1

Whole film. Lot 3

10

109 ± 1.40

10.9

Half film, Lot 1

10

106 ± 2.44

10.4

Half film. Lot 2

10

105 ± 2.85

10.3

Halt film. Lot 3

10

106 ± 2,21

9.8

The acceptance value (AV) is calculated according to United States Pharmacopeia Chapter <905>,
and the passing criteria is AV ^5.

TABLE 5.
CONTENT UNIFORMITY RESULTS OF NALOXONE IN WHOLE
AND HALF FILMS.

STABILITY OF SPLIT FILMS
Based on the chemical structures (Figure 1) and the forced stabil
ity study results (Methods section), there was a potential concern
for the stability of buprenorphine and naloxone once the films are
removed from the original packaging. The physical stability of the
films was also unknown. A 7-day stability study of the split films
was conducted to address these concerns. The half films were
stored in polybags at room temperature. Based on visual inspec
tion, the films appeared to lose some flexibility over seven days, but
they did not become too fragile for normal handling. The chemical
stability was monitored by the stability-indicating HPLC assay, and
the results are shown in TABLE 6. Both buprenorphine and naloxone
retained >97.7% of their initial strengths over the study period.

BUPRENORPHINE
CONTENT
(% LABEL CLAIM),
MEAN ± SD

SAMPLE

NUMBER
OF UNITS

NALOXONE
CONTENT
(% LABEL CLAIM),
MEAN ± SD

AV

Whole film. Lot 1

10

106 ± 1.61

8.2

Whole film. Lot 2

10

107 ± 2,09

10.5

Whole film. Lot 3

10

109 ± 1.50

11.1

Half film. Lot 1

10

107 ± 2.14

10.2

Half film. Lot 2

10

108 ± 2.09

11.5

Half film. Lot 3

10

108 ± 0.78

8.4

The acceptance value (AV) is calculated according to United States Pharmacopeia Chapter <905>,
and the passing criteria is AV ^5.
SD • standard deviation
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TABLE 6.
CHEMICAL STABILITY OF THE TWO ACTIVE INGREDIENTS
IN THE HALF FILMS STORED IN POLYBAGS OVER 7 DAYS
AT ROOM TEMPERATURE (n=3 FOR EACH TIME POINT).
ACTIVE
INGREDIENT

INITiAI. DRUG
CONTENT CMG)^
MEAN ± SD

2.

% INITIAL DRUG CONTENT

REMAINING^ MEAN ± SD

DAY I

DAY 3

DAY T

Buprenorphine

4.28 + 0.09

100.8 ± 0.8

99.5 ± 2.6

100.5 ± 3.6

Naloxone

108 ± 0.01

99.6 ± 1.3

97.7 ± 3.4

99.0 ± 2.8

3.

SD = standard deviation

STUDY LIMITATIONS
First, this study only evaluated one strength (8 mg buprenorphine and 2 mg naloxone) of Suboxone films. It is unknown if these
findings also apply to the other strengths, since the package insert
states that there is some variation in film composition between
strengths.^ Secondly, due to regulatory challenges to obtain the
pure buprenorphine powder, this study used a single Suboxone
film to prepare the HPLC calibration standards on each analysis
day. This may explain why the average drug content was >100% of
the label claim in all samples (TABLES A AND 5). Nevertheless, this was
taken into account for the calculation of the acceptance values, and
the overall conclusions remained the same. In future studies, stan
dards should be prepared using pure drug if attainable or a pooled
solution of multiple films to improve accuracy of the standards.

4.

5.
6.

7.

8.
9.

Conclusion
Four cutting methods were found to be acceptable to split the
Suboxone film (8 mg/2 mg strength) into half fractions based on
weight variation data. Additionally, the content uniformity of
the actives in the half films was confirmed for the ruler/razor cut
method. The half films were stable for at least seven days when
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